Key Takeaways NVO's Wegovy pill becomes the first oral GLP-1 for obesity and plans a U.S. launch in early January 2026.FDA approved NVO's once-daily oral Wegovy to cut excess weight, maintain loss and reduce cardiovascular risk.Novo Nordisk's OASIS 4 study showed 16.6% mean weight loss, with one in three patients losing 20% or more.Novo Nordisk (NVO) announced the FDA approval of Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction in the long term, and ...